Exchanging Knowledge
Cooperations
The neuroscientists of the INM-2 closely cooperate with renowned scientists from national and international research facilities.
Molecular Neuroimaging
J. Jordan, J. Tank, EM. Elmenhorst, D. Aeschbach, J. Rittweger (Institut für Luft- und Raumfahrtmedizin, Deutsches Zentrum für Luft- und Raumfahrt, Köln)
C. Saft, J. Achenbach, G. Ellrichmann (Neurogenetik, Klinik für Neurologie, Universitätsklinikum Bochum)
F. C. Binkofski, Klinische Kognitionsforschung, Neurologische Klinik, RWTH Aachen
T. v. Eimeren, Nuklearmedizinische Klinik, Universität zu Köln
P. Carloni, G. Rossetti (Institut für Neurowissenschaften und Medizin (IAS-5 / INM-9), Forschungszentrum Jülich)
B. Neumaier, J. Ermert, M. Holschbach, D. Bier, B. Drewes, T. Wicher (Institut für Neurowissenschaften und Medizin (INM-5), Forschungszentrum Jülich)
P. Rosa-Neto (Translational Neuroimaging Laboratory, Department of Neurology and Neurosurgery and Psychiatry, McGill University, Montreal, Canada)
J. Deckert (Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Universität Würzburg)
Ch. Hohoff (Labor für Molekulare Psychiatrie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universität Münster)
H.-P. Landolt (Institut für Pharmakologie und Toxikologie, Universität Zürich, Schweiz)
J. Verhaeghe (Nuclear Medicine/MICA, University of Antwerp, Antwerpen, Belgien)
G. Knudsen, C. Svarer (Neurobiology Research Unit, Rigshospitalet, Copenhagen University Hospital, Kopenhagen, Dänemark)
A. Phillips (Monash Institute of Cognitive and Clinical Neurosciences in the School of Psychological Sciences, Monash University, Melbourne, Australien)
A. Cukkemane, D. Willbold (Institut für Biologische Informationsprozesse (IBI-7), Forschungszentrum Jülich)
A. Ramírez (Molecular Neuropsychiatry, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Uniklinik Köln)
Using PET for the Evaluation of Innovative Analgetics with Dual Mode of Action (Dual²PET)
Innovative drugs targeting two modes of action based on one chemical structure are a promising novel therapeutic approach in medicine. These ‚dual modulators’ come with the decisive advantage of avoiding the application of different drugs with individual pharmacodynamics and dosing. Thus, dual modulators prevent patients from problems of differential intake and interactions of medications.
The consortium is funded by the European Union and the federal state of Northrhine Westfalia. It aims at using positron emission tomography (PET), a non-invasive, repeatedly applicable and quantitative method, as a genuine technique in the development and optimization of novel drugs with dual modes of action. This novel approach in drug development is targeting at faster and more predictable means to evaluate and provide innovative drugs.
Project partners are Forschungszentrum Jülich (INM-2, INM-5, INM-9) and the companies Grünenthal (Aachen) and Taros Chemicals (Dortmund). The project is supported by Leitmarktagentur NRW and Projektträger Jülich.
